BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 12160136)

  • 1. Epithelial differentiation and proliferative potential in spinal ependymomas.
    Takeuchi H; Kubota T; Sato K; Llena JF; Hirano A
    J Neurooncol; 2002 May; 58(1):13-9. PubMed ID: 12160136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity and specificity of epithelial membrane antigen staining patterns in ependymomas.
    Hasselblatt M; Paulus W
    Acta Neuropathol; 2003 Oct; 106(4):385-8. PubMed ID: 12898159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical study of ependymal neoplasms: histological subtypes and glial and epithelial characteristics.
    Kaneko Y; Takeshita I; Matsushima T; Iwaki T; Tashima T; Fukui M
    Virchows Arch A Pathol Anat Histopathol; 1990; 417(2):97-103. PubMed ID: 1695040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunophenotype of ependymomas.
    Vege KD; Giannini C; Scheithauer BW
    Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):25-31. PubMed ID: 10937045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
    Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
    Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostic use of D2-40 and annexin-1 in ependymal tumors].
    Wang YF; Piao YS; Lu DH; Chen L; Wang W; Yang H; Wei LF
    Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):595-8. PubMed ID: 22177242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ependymomas of the spinal region in adults: Clinical and pathological features and MYCN expression levels in spinal ependymomas and myxopapillary ependymomas.
    Topel G; Dirilenoğlu F; Sevin İE; Kahraman A
    Ann Diagn Pathol; 2024 Jun; 70():152299. PubMed ID: 38555652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The growth potential of ependymomas with varying grades of malignancy measured by the Ki-67 labelling index and mitotic index.
    Schröder R; Ploner C; Ernestus RI
    Neurosurg Rev; 1993; 16(2):145-50. PubMed ID: 8345908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the recurrence of ependymomas from the bromodeoxyuridine labeling index.
    Asai A; Hoshino T; Edwards MS; Davis RL
    Childs Nerv Syst; 1992 Aug; 8(5):273-8. PubMed ID: 1394266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spinal cord ependymomas and myxopapillary ependymomas in the first 2 decades of life: a clinicopathological and immunohistochemical characterization of 19 cases.
    Stephen JH; Sievert AJ; Madsen PJ; Judkins AR; Resnick AC; Storm PB; Rushing EJ; Santi M
    J Neurosurg Pediatr; 2012 Jun; 9(6):646-53. PubMed ID: 22656257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myxopapillary ependymoma with anaplastic features.
    Awaya H; Kaneko M; Amatya VJ; Takeshima Y; Oka S; Inai K
    Pathol Int; 2003 Oct; 53(10):700-3. PubMed ID: 14516321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myxopapillary ependymomas: a clinicopathologic study of 14 cases including MIB-1 and p53 immunoreactivity.
    Prayson RA
    Mod Pathol; 1997 Apr; 10(4):304-10. PubMed ID: 9110291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of cervicomedullary junction tanycytic ependymoma associated with marked cyst formation.
    Ito T; Ozaki Y; Nakagawara J; Nakamura H; Tanaka S; Nagashima K
    Brain Tumor Pathol; 2005; 22(1):29-33. PubMed ID: 18095101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential involvement of protein 4.1 family members DAL-1 and NF2 in intracranial and intraspinal ependymomas.
    Singh PK; Gutmann DH; Fuller CE; Newsham IF; Perry A
    Mod Pathol; 2002 May; 15(5):526-31. PubMed ID: 12011257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The proliferative potential of human ependymomas measured by in situ bromodeoxyuridine labeling.
    Nagashima T; Hoshino T; Cho KG; Edwards MS; Hudgins RJ; Davis RL
    Cancer; 1988 Jun; 61(12):2433-8. PubMed ID: 3284636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical markers for prognosis of ependymal neoplasms.
    Korshunov A; Golanov A; Timirgaz V
    J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial differentiation in intraspinal meningiomas.
    Takeuchi H; Llena JF; Hirano A
    Brain Tumor Pathol; 1997; 14(2):113-7. PubMed ID: 15726789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological spectrum of ependymomas and correlation of p53 and Ki-67 expression with ependymoma grade and subtype.
    Suri VS; Tatke M; Singh D; Sharma A
    Indian J Cancer; 2004; 41(2):66-71. PubMed ID: 15318011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of the histological and molecular characteristics of ependymal tumors: a single institution case series from China.
    Xi S; Sai K; Hu W; Wang F; Chen Y; Wang J; Zeng J; Chen Z
    BMC Cancer; 2019 Jul; 19(1):717. PubMed ID: 31324163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry.
    Prayson RA
    Ann Diagn Pathol; 1999 Feb; 3(1):11-8. PubMed ID: 9990108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.